In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on Zymeworks (ZYME – Research Report), with a price target of $19.00. The company's shares closed last Thursday at $6.37, close to its 52-week low of $4.56. According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of -11.8% and a 37.0% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $23.63 average price target, implying a 301.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-zymeworks-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Zymeworks Charts.
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Zymeworks Charts.